[June 12, 2017] |
|
Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
Alkermes
plc (NASDAQ: ALKS) today announced the initiation of study 217, a
phase 3b trial of ALKS 5461, a once-daily, oral investigational medicine
with a novel mechanism of action for the adjunctive treatment of major
depressive disorder (MDD). The study will evaluate the efficacy and
safety of ALKS 5461 in patients suffering from MDD who have had an
inadequate response to commonly prescribed drugs for depression,
including selective serotonin reuptake inhibitors (SSRIs) or
serotonin-norepinephrine reuptake inhibitors (SNRIs). In addition to the
traditional Montgomery-Åsberg Depression Rating Scale (MADRS) for
assessing improvement in depression symptoms, study 217 will include
scales to further evaluate ALKS 5461's potential benefits on mood and
associated behavioral domains known to be regulated by endogenous opioid
modulation. The company also reiterated plans to submit a New Drug
Application (NDA) for ALKS 5461 for the adjunctive treatment of MDD to
the U.S. Food and Drug Administration (FDA) by year-end 2017.
"Opioid modulation represents a new mechanism for the treatment of
depression that may provide benefits beyond those observed with
traditional antidepressants. Along with the clinical community, we are
looking forward to further exploring ALKS 5461's potential in regulating
domains such as social connection, resilience and anhedonia. Study 217
includes scales and endpoints to help elucidate ALKS 5461's potential
effects on these specific mood domains where opioid modulation may yield
singular benefit," stated Elliot Ehrich, M.D., Executive Vice President,
Research and Development of Alkermes. "In parallel, we plan to meet with
the FDA in July for our scheduled pre-NDA meeting and are preparing our
New Drug Application for ALKS 5461 for the adjunctive treatment of MDD."
Study 217 is a phase 3b, multinational, randomized, double-blind,
placebo-controlled clinical trial that will evaluate the efficacy,
safety and tolerability of ALKS 5461 as adjunctive treatment in patients
with MDD. The 11-week, 2-stage study will randomize up to 325 patients
and incorporates design features informed by the FORWARD pivotal program
to help ensure rigorous patient selection, monitoring and evaluation.
The primary objective of the study is to assess ALKS 5461's ability to
improve depressive symptoms, as measured by MADRS-6 and MADRS-10.
Specific scales to evaluate additional potential benefits of ALKS 5461
included in study 217 are the Connor-Davidson Resilience Scale
(CD-RISC), Snaith-Hamilton Pleasure Scale (SHAPS), Quality of Life
Enjoyment and Satisfaction Questionnaire-Short Form, rief Pain
Inventory-Short Form (BPI-SF), and the Clinical Global
Impression-Severity (CGI (News - Alert)-S) and Clinical Global Impression-Improvement
(CGI-I) scales.
About ALKS 5461 ALKS 5461 is a
proprietary, investigational, once-daily oral medicine that acts as a
balanced neuromodulator in the brain and represents a novel mechanism of
action for the adjunctive treatment of MDD. ALKS 5461 consists of
samidorphan and buprenorphine, and is designed to rebalance brain
function that is dysregulated in the state of depression. In October
2013, the FDA granted Fast Track status for ALKS 5461 for the adjunctive
treatment of MDD in patients with an inadequate response to standard
antidepressant therapies.
About MDD According to the DSM (News - Alert)-5® (Diagnostic
and Statistical Manual of Mental Disorders, Fifth Edition),
major depressive disorder (MDD) is a condition in which patients exhibit
depressive symptoms, such as a depressed mood or a loss of interest or
pleasure in daily activities consistently for at least a two-week
period, and demonstrate impaired social, occupational, educational or
other important functioning. An estimated 17 million people in the U.S.
suffer from MDD in a given year,1,2 the majority of whom may
not adequately respond to initial antidepressant therapy.3
About Alkermes plc Alkermes
plc is a fully integrated, global biopharmaceutical company developing
innovative medicines for the treatment of central nervous system (CNS)
diseases. The company has a diversified commercial product portfolio and
a substantial clinical pipeline of product candidates for chronic
diseases that include schizophrenia, depression, addiction and multiple
sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D
center in Waltham, Massachusetts; a research and manufacturing facility
in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
For more information, please visit Alkermes' website at www.alkermes.com.
Note Regarding Forward-Looking Statements Certain
statements set forth in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, but not limited to,
statements concerning: the therapeutic value and commercial potential of
ALKS 5461, and the development and regulatory plans and timelines,
including the timing of submission of the NDA, for ALKS 5461. You are
cautioned that forward-looking statements are inherently uncertain.
Although the company believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its
business and operations, the forward-looking statements are neither
promises nor guarantees and they are necessarily subject to a high
degree of uncertainty and risk. Actual performance and results may
differ materially from those expressed or implied in the forward-looking
statements due to various risks and uncertainties. These risks and
uncertainties include, among others: whether preclinical and clinical
results for ALKS 5461 will be predictive of future clinical study
results and commercial potential of ALKS 5461; whether future clinical
trials for ALKS 5461 will be completed on time or at all; potential
changes in cost, scope and duration of the ALKS 5461 clinical
development program; whether ALKS 5461 could be shown ineffective or
unsafe during clinical studies; whether the preclinical and clinical
results of ALKS 5461 will meet the regulatory requirements for approval;
whether regulatory submissions may occur or be submitted in a timely
manner; and those risks and uncertainties described under the heading
"Risk Factors" in the company's Annual Report on Form 10-K for the year
ended Dec. 31, 2016 and Quarterly Report on Form 10-Q for the quarter
ended Mar. 31, 2017 and in subsequent filings made by the company with
the U.S. Securities and Exchange Commission (SEC (News - Alert)), which are available
on the SEC's website at www.sec.gov.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. Except as required by law, the company disclaims any
intention or responsibility for updating or revising any forward-looking
statements contained in this press release.
DSM-5® is a registered trademark of
the American Psychiatric Association.
1 Kessler RC et al (2005) Archives of General
Psychiatry, Jun; 62 (6), pp. 617-27. 2 U.S. Census. 3 Rush
AJ et al (2007) Am J. Psychiatry, 163:11, pp. 1905-1917
(STAR (News - Alert)*D Study).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170612005154/en/
[ Back To TMCnet.com's Homepage ]
|